GlassScriptPhysician profile
M Alan Sharif
NPI 1013910546
$75,094.74
in general payments reported to CMS, 2019-2025
45 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,407 · 2021: $5,330 · 2022: $15K · 2023: $9,885 · 2024: $10K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $26K · Food and Beverage: $10K · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $25,872.25 |
| Food and Beverage | $10,449.65 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $24,786.09 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Hawkone |
| Abbott Laboratories | $15,786.39 | 2019-2025 | Optis, Supera, Acculink |
| Janssen Pharmaceuticals, INC | $11,307.72 | 2019-2024 | Xarelto |
| Penumbra, INC. | $10,179.87 | 2021-2025 | Indigo System, Penumbra System |
| Medtronic Vascular, INC. | $3,966.12 | 2019-2020 | |
| Boston Scientific Corporation | $1,848.89 | 2019-2024 | Eluvia, Rotapro |
| Cvrx, INC. | $1,738.86 | 2023-2024 | Barostim Neo System |
| Amgen INC. | $1,241.39 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $364.59 | 2020-2024 | Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $347.26 | 2019-2025 | |
| Philips North America LLC | $340.39 | 2019-2025 | Philips Laser System |
| Amarin Pharma, INC. | $297.02 | 2019-2021 | |
| Truvic Medical, INC. | $271.96 | 2022 | |
| Pfizer INC. | $235.55 | 2019-2024 | |
| Abiomed | $210.13 | 2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $200.98 | 2019-2024 | Entre Plus, Flexitouch Plus |
| Imperative Care, INC | $194.76 | 2024 | Symphony Catheter, Prodigy Catheter |
| E.R. Squibb & Sons, L.L.C. | $189.73 | 2021-2025 | |
| Cook Medical LLC | $160.72 | 2022 | |
| Sanofi-Aventis U.S. LLC | $135.78 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $131.26 | 2021-2023 | Verquvo |
| Endologix LLC | $121.66 | 2024 | Torus Stent Graft System, Endocross Device |
| Smith+Nephew, INC. | $120.72 | 2019 | |
| Shockwave Medical, INC | $101.11 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Gt Medical Technologies, INC | $94.18 | 2023 | Gammatile |
| Biosense Webster, INC. | $89.27 | 2025 | Carto 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.42 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.06 | 2019-2025 | Jardiance |
| Cordis US Corp. | $69.51 | 2023-2024 | Saber, Infiniti, Precise Pro Rx |
| Esperion Therapeutics, INC. | $62.34 | 2020-2021 | |
| Gilead Sciences, INC. | $41.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.03 | 2021-2022 | |
| Novo Nordisk INC | $31.08 | 2024 | Wegovy |
| Acist Medical Systems, INC. | $29.46 | 2022 | |
| Daiichi Sankyo INC. | $25.08 | 2023 | Injectafer |
| Osiris Therapeutics INC. | $24.70 | 2019 | |
| Braemar Manufacturing, LLC | $21.65 | 2019 | |
| Surmodics, INC. | $21.24 | 2024 | Pounce Venous Thrombectomy System |
| Actelion Pharmaceuticals US, INC. | $18.63 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.91 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $15.64 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $14.92 | 2024 | Arcalyst |
| Teleflex LLC | $14.84 | 2023 | Guideliner |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2021 | |
| Bardy Diagnostics, INC. | $5.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Sharif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.